Real-World Analysis of the Clinical and Economic Impact of the 21-Gene Recurrence Score (RS) in Invasive Lobular Early-Stage Breast Carcinoma in Ireland
Conclusions: The use of this test resulted in a 75% reduction in chemotherapy and a significant cost savings in our publicly funded health system.PMID:38534931 | DOI:10.3390/curroncol31030098
Source: Current Oncology - Category: Cancer & Oncology Authors: Lynda M McSorley Mehala Tharmabala Fathiya Al Rahbi Fergus Keane Denis Evoy James G Geraghty Jane Rothwell Damian P McCartan Megan Greally Miriam O'Connor Deirdre O'Mahony Maccon Keane Michael John Kennedy Seamus O'Reilly Steve J Millen John P Crown Cathe Source Type: research
More News: Breast Cancer | Breast Carcinoma | Cancer | Cancer & Oncology | Carcinoma | Chemotherapy | Genetics | HER2 | Hormonal Therapy | Hormones | Ireland Health | Study